show episodes
 
Showcasing major breakthroughs in the field, Project Oncology® educates and assists the heroes who dedicate their lives to pioneering new advancements in the war against cancer. Hear from leading oncologists as they discuss essential screening and diagnostic tools, emerging therapies, counseling strategies, and more.
 
Loading …
show series
 
Guest: Mariana Chavez MacGregor, MD, MSC The healthcare disparity crisis in the breast cancer field has prevented the benefits of therapeutic advancements from being equally distributed throughout all populations. What can we do to overcome this obstacle? Dr. Mariana Chavez MacGregor, Associate Professor at the University of Texas MD Anderson Cance…
 
Host: Jacob Sands, MD Guest: Christopher Lathan, MD, MS, MPH Oftentimes, a patient’s zip code is a better indicator of health than blood pressure or genetics, highlighting a significant disparity among communities. How are barriers such as systemic racism contributing to this disparity, and what can we do to change that? Dr. Jacob Sands is joined b…
 
Guest: Christopher Lathan, MD, MS, MPH Healthcare professionals have found that zip code is a better indicator of health for many patients rather than cholesterol or genetics, highlighting a significant disparity in the field of medicine. What can we do to overcome this obstacle? Dr. Christopher Lathan, Associate Medical Director of the Dana Farber…
 
Host: Jacob Sands, MD Guest: Taofeek K. Owonikoko, MD, PhD, MSCR After years without new approvals, advancements in small cell lung cancer are at the forefront of oncology. But what do these therapeutic developments mean for the field? Dr. Taofeek Owonikoko, professor and vice-chair for faculty development in the Department of Hematology and Medica…
 
Host: Jennifer Caudle, DO Guest: Suma Satti, MD Small cell lung cancer is an aggressive form of lung cancer, and until recently therapeutic options have been limited. Joining Dr. Jennifer Caudle to discuss the role of immunotherapy in combination with chemotherapy in the treatment of this devastating disease as well as recent data from a clinical t…
 
Host: Edward Chu, MD Guest: Michael J. Overman, MD Recent immunotherapy approvals have changed the treatment paradigm for first and subsequent lines of treatment for patients with microsatellite-high or mismatch repair deficient metastatic colorectal cancer. Join us as we deep dive into recent and newly emergent data to better understand how to bri…
 
Host: Jacob Sands, MD Guest: Nabil F. Saba, MD Since head and neck cancer is still to a large extent a surgical disease, the COVID-19 pandemic had an immediate impact on its management. Here to share how he pivoted his approach and how the pandemic might impact the future of head and neck cancer care is Dr. Nabil Saba, a Professor and Vice Chair fo…
 
Host: Jacob Sands, MD Guest: Nabil F. Saba, MD Emerging research on head and neck cancer has moved away from HPV-negative diseases upon the discovery of HPV-positive diseases, specifically HPV-positive oropharynx cancer. What do we know about managing and treating this disease? Dr. Nabile Saba dives into treatment considerations, specifically immun…
 
Host: Jacob Sands, MD Guest: Therese T. Bevers, MD Fear of the COVID-19 pandemic has led to added safety precautions that have prevented patients from receiving much-needed cancer screenings. How will this impact the field of oncology, and what can we do to encourage patients to get their screenings? Dr. Therese Beavers, Medical Director of the Can…
 
Host: Paul P. Doghramji, MD, FAAFP Guest: Corey S. Cutler, MD, MPH, FRCPC Guest: Doris M. Ponce, MD Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of morbidity and mortality. Although systemic corticosteroids are traditional first-line treatment for aGVHD, …
 
Host: Stephen Cohen, MD Guest: Thomas C. Wright, Jr., MD Regardless of the cervical cancer screening (CCS) approach used, effective triage tests are needed to improve diagnostic evaluation. An ideal screening and triage approach should identify as many precancerous lesions as possible while referring as few women as possible to colposcopy. Learn ho…
 
Host: Robert Mocharnuk, MD Guest: Richard S. Finn, MD Guest: Amit Singal, MD, MS The majority of patients with HCC have advanced disease at diagnosis and aren’t candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Advances in immune checkpoint inhibitor therapy are transforming the way clinic…
 
Host: Scott Kopetz, MD, PhD Guest: Prof Eric Van Cutsem, MD, PhD Guest: Josep Tabernero, MD, PhD Dr. Scott Kopetz, Prof. Eric Van Cutsem, and Dr. Josep Tabernero engage in a panel discussion with a focus on the practice-changing initial and subsequently updated mature findings from the BEACON trial. These pivotal findings alter the standard of care…
 
Host: Scott Kopetz, MD, PhD Guest: Prof Eric Van Cutsem, MD, PhD Dr. Scott Kopetz and Prof. Eric Van Cutsem evaluate both the initial and updated pivotal outcomes from the BEACON trial in second- and third-line BRAF V600E-mutated metastatic colorectal cancer. They extend their discussion of these practice-changing results to include the early-stage…
 
Host: Richard T. Penson, MD, MRCP Guest: Linda R. Duska, MD, MPH There remains a critical unmet need for effective therapies following the recurrence of endometrial cancer. In this activity, Drs. Linda Duska and Richard Penson assess the role of immunotherapy and targeted therapies in managing advanced endometrial cancers, as well as the importance…
 
Host: Mark A. Socinski, MD Guest: Alexander Drilon, MD There are now multiple biomarker-defined patient subgroups in advanced non-small cell lung cancer (NSCLC), including RET rearrangements, and there is growing evidence that treatment with targeted therapies has significant clinical outcomes. In response to current rapid changes in the field of N…
 
Host: Sara Hurvitz, MD Guest: Jacob Sands, MD Anti-HER2 therapy is well established as a first-line approach for many patients with metastatic breast cancer. HER2 has now been identified as an oncogenic driver across multiple malignancies, including non-small cell lung cancer, colorectal cancer, and gastric cancer. Dr. Sara A. Hurvitz and Dr. Jacob…
 
Host: Mark A. Socinski, MD Guest: Helena Yu, MD Advances in treatment and new insights into the biology of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have led to the development of treatments that significantly extend overall survival. In this discussion, Drs. Mark Socinski and Helena Yu cover the l…
 
Host: Mark A. Socinski, MD Guest: Gilberto de Lima Lopes Junior, MD, MBA, FAMS Advanced non-small cell lung cancer (NSCLC) remains incurable; however, advances in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This discussion between Drs…
 
Host: William J. Gradishar MD, FASCO, FACP Guest: Peter Schmid, FRCP, MD, PhD This activity will enhance knowledge and competence in the management of HER2-positive breast cancer. Dr. William Gradishar and Dr. Peter Schmid engage in a lively discussion regarding the latest clinical data supporting novel investigational and approved therapies for th…
 
Host: Mark A. Socinski, MD Guest: Edward B. Garon, MD, MS Advanced non-small cell lung cancer (NSCLC) remains incurable, but overall survival is improving, as shown by new scientific and clinical data that are emerging on the use of checkpoint inhibitors in the frontline setting and after disease progression. This discussion between Drs. Mark Socin…
 
Host: Warner K. Huh, MD Guest: Deborah K. Armstrong, MD Guest: Robert L. Coleman, MD, FACOG, FACS The approval of PARP inhibitors for maintaining response to chemotherapy and in recurrent disease has improved outcomes for patients. Additionally, ongoing and conclusive studies are paving the way for PARP inhibitor use earlier in therapy. This activi…
 
Host: Mark A. Socinski, MD Guest: Suresh S. Ramalingam, MD While advanced non-small cell lung cancer remains incurable, innovations in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This activity will discuss the new scientific and clini…
 
Host: Stephen M. Cohen, MD, FACOG Guest: Thomas C. Wright, Jr., MD Cervical cancer screening (CCS) methods include cytology alone, use of primary high-risk HPV testing alone, and co-testing. Regardless of the screening approach used, effective triage tests are needed to decide who among the presumptive positive women should receive further diagnost…
 
Host: Peter H. O'Donnell, MD Guest: Daniel P. Petrylak, MD The treatment of urothelial carcinoma, the most common type of bladder cancer, has historically been limited to platinum-based chemotherapy; however, the majority of patients will relapse. And while immunotherapy has offered survival benefits to patients, not all patients respond to immune …
 
Host: John J. Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discuss…
 
Host: Brian P. McDonough, MD, FAAFP Human papillomavirus (HPV) infection remains one of the most common sexually transmitted infections in both females and males, with about 9 in 10 people contracting HPV at some point in their lives. Host Dr. Brian McDonough is joined by Samantha Gottlieb, medical anthropologist and author of Not Quite a Cancer Va…
 
Host: Shira Johnson, MD Guest: Ronald DeMatteo, MD, FACS A Gastrointestinal Stromal Tumor (GIST) is a rare sarcoma that begins in the digestive tract or stomach, with an incident rate in the United States of approximately 4,000 to 6,000 cases per year. Since these tumors behave differently from other gastrointestinal cancers, they require a special…
 
Host: Shira Johnson, MD Guest: Robert Vonderheide, MD For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer. But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has e…
 
Host: John J. Russell, MD Guest: Harish Lavu, MD Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. This is due, in large part, to its insidious onset and subtle presentation even at late stages, many symptoms of which are often attributed to common and less serious conditions in …
 
Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at th…
 
Host: Jennifer Caudle, DO Guest: Major Kenneth Lee, IV, MD, PhD Though a relatively rare disease, pancreatic cancer remains at the forefront of clinical discussion due to its highly aggressive nature. Dr. Major Kenneth Lee, Assistant Professor of Surgery at Penn Medicine, estimates that pancreatic cancer will become the number 2 cause of cancer dea…
 
Host: Matt Birnholz, MD Several new screening tests have been developed to help doctors find colorectal cancer early when it's most treatable and can reduce the burden of this disease and the death toll nationwide. Host Dr. Matt Birnholz chats with Dr. John Kisiel, gastroenterologist and Assistant Professor of Medicine at Mayo Clinic College of Med…
 
Host: Matt Birnholz, MD Guest: Ari Brooks, MD Guest: Brian Englander, MD Host Dr. Matt Birnholz is joined by Dr. Ari Brooks, Director of Endocrine and Oncology Surgery and Director of the Integrated Breast Center at Pennsylvania Hospital, and Dr. Brian Englander, Clinical Assistant Professor and Chair of the Department of Radiology at Pennsylvania …
 
Host: Matt Birnholz, MD Guest: Taine Pechet, MD Dr. Taine Pechet, chief of surgery at Penn Presbyterian Medical Center and associate professor of clinical surgery at Penn Medicine joins host Dr. Matt Birnholz to discuss his thoughts on who should be regularly screen for lung cancer and the various diagnostic techniques from his perspective as a tho…
 
Host: Matt Birnholz, MD Cannabis is gaining increased acceptance within the medical community for pain relief and other supportive care applications. But for oncology specialties, the use of cannabis may additionally extend into therapeutic purposes for patients. From the floors of the A4M Conference in Las Vegas, Dr. Matt Birnholz speaks with Cons…
 
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG From the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 75. Her lifetime chance of dying from ovarian can…
 
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG What is the role and importance of the Ob-Gyn Oncologist, especially for women diagnosed with pelvic cancers? What are some barriers patients face in seeing an Ob-Gyn Oncoloogist? And how can clinicians better partner with this group of specialists? In this episode, host Dr. Renee Allen explores an…
 
Host: Matt Birnholz, MD Guest: Edward R. Sauter, MD, PhD, MHA In the clinical arena, discussions on breast cancer prevention and treatment often center on what is considered most "cutting edge," from genetic mechanisms of disease to new combination pharmacotherapies to breast-conserving surgical innovations. But another field of study, targeting th…
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login